Skip to main content
Leo Luznik, MD, Hematology, Houston, TX

LeoLuznikMD

Hematology Houston, TX

Hematologic Oncology

Associate Professor of Oncology at Johns Hopkins University School of Medicine

Dr. Luznik is on Doximity

As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.

  • Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
  • Connect with colleagues in the same hospital or clinic.
  • Read the latest clinical news, personalized to your specialty.

See Dr. Luznik's full profile

Already have an account?

  • Office

    1919 Old Spanish Trl
    Houston, TX 77054
    Phone+1 713-798-4321
    Fax+1 410-614-1005

Education & Training

  • Johns Hopkins University
    Johns Hopkins UniversityFellowship, Hematology and Medical Oncology, 1998 - 2000
  • Johns Hopkins University
    Johns Hopkins UniversityFellowship, Hematology and Medical Oncology, 1997 - 1998
  • University of Arizona College of Medicine-Tucson
    University of Arizona College of Medicine-TucsonResidency, Internal Medicine, 1994 - 1997
  • UC San Diego Medical Center - Hillcrest
    UC San Diego Medical Center - HillcrestPost-Doctoral Fellowship, 1991 - 1994
  • University of Zagreb Faculty of Medicine
    University of Zagreb Faculty of MedicineClass of 1990

Certifications & Licensure

  • CA State Medical License
    CA State Medical License 1996 - Present
  • MD State Medical License
    MD State Medical License 1997 - 2026
  • TX State Medical License
    TX State Medical License 2024 - 2026

Clinical Trials

Publications & Presentations

PubMed

Journal Articles

  • The European Society for Blood and Marrow Transplantation (EBMT) Consensus Recommendations for Donor Selection in Haploidentical Hematopoietic Cell Transplantation  
    Leo Luznik, Karen Ballen, Asad Bashey, Hillard M Lazarus, Bipin N Savani, Rizwan Romee, Ephraim J Fuchs, Nature
  • Small-Molecule BCL6 Inhibitor Effectively Treats Mice with Non-Sclerodermatous Chronic Graft-Versus-Host Disease  
    Joseph H Antin, Bruce Blazar, Leo Luznik, John Koreth, Ivan Maillard, Robert J Soiffer, James E Bradner, Jonathan S Serody, Jerome Ritz, Blood

Abstracts/Posters

  • Final Clinical Results of a Phase II Study of High Dose Cytarabine Followed By Pembrolizumab in Relapsed/Refractory AML
    Leo Luznik, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/9/2019
  • Multi-Center Phase 2 Study of Pembroluzimab (Pembro) and Azacitidine (AZA) in Patients with Relapsed/Refractory Acute Myeloid Leukemia (AML) and in Newly Diagnosed (_6...
    Leo Luznik, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/9/2019
  • BMT CTN 1803: Haploidentical Natural Killer Cells (CSTD002) to Prevent Post-Transplant Relapse in AML and MDS (NK-REALM)
    Leo Luznik, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/9/2019
  • Join now to see all

Lectures

  • Spoiled for Choice: Donor Selection for Allogeneic Stem Cell Transplantation 
    61st Annual American Society of Hematology Meeting - Orlando, FL - 12/7/2019

Press Mentions

  • Short Telomere Syndromes Cause a Primary T Cell Immunodeficiency
    Short Telomere Syndromes Cause a Primary T Cell ImmunodeficiencyOctober 22nd, 2020
  • Drug Regimen Enough to Control Immune Disease After Some Bone Marrow Transplants
    Drug Regimen Enough to Control Immune Disease After Some Bone Marrow TransplantsOctober 8th, 2014
  • How Common Chemo Drug Thwarts Graft Rejection in Bone Marrow Transplants
    How Common Chemo Drug Thwarts Graft Rejection in Bone Marrow TransplantsNovember 13th, 2013
  • Join now to see all